Iclusig (ponatinib)

News alerts, weekly reports and conference planners

Company:

Incyte, Otsuka, Takeda

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Acute Lymphocytic Leukemia	ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	ponatinib Sensitive: B - Late Trials ponatinib Sensitive : B	ponatinib Sensitive: B - Late Trials ponatinib Sensitive : B
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: C1 - Off-label ponatinib Sensitive : C1	ponatinib Sensitive: C1 - Off-label ponatinib Sensitive : C1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
FGFR2 S252W	Endometrial Cancer	FGFR2 S252W	Endometrial Cancer	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
BCR-ABL1 T315I + ABL1 E255V	Acute Lymphocytic Leukemia	BCR-ABL1 T315I + ABL1 E255V	Acute Lymphocytic Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
BCR-ABL1 T315I + ABL1 E255K	Acute Lymphocytic Leukemia	BCR-ABL1 T315I + ABL1 E255K	Acute Lymphocytic Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
BCR-ABL1 T315M	Acute Lymphocytic Leukemia	BCR-ABL1 T315M	Acute Lymphocytic Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
BCR-ABL1 V289A	Acute Lymphocytic Leukemia	BCR-ABL1 V289A	Acute Lymphocytic Leukemia	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3
IKZF1 deletion + CDKN2A deletion	Acute Myelogenous Leukemia	IKZF1 deletion + CDKN2A deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion + VPREB1 deletion	Acute Myelogenous Leukemia	IKZF1 deletion + VPREB1 deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion	Acute Myelogenous Leukemia	IKZF1 deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
BCR-ABL1 Q252H + BCR-ABL1 V299L	B Acute Lymphoblastic Leukemia	BCR-ABL1 Q252H + BCR-ABL1 V299L	B Acute Lymphoblastic Leukemia	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3
BCR-ABL1 E255V	B Acute Lymphoblastic Leukemia	BCR-ABL1 E255V	B Acute Lymphoblastic Leukemia	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3
BCR-ABL1 mutation	Acute Myelogenous Leukemia	BCR-ABL1 mutation	Acute Myelogenous Leukemia	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3
ABL1 E255K	Acute Lymphocytic Leukemia	ABL1 E255K	Acute Lymphocytic Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
BCR-ABL1 E255K	Acute Lymphocytic Leukemia	BCR-ABL1 E255K	Acute Lymphocytic Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3
FGFR1 overexpression	Lung Cancer	FGFR1 overexpression	Lung Cancer	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials ponatinib + blinatumomab Sensitive : C3	ponatinib + blinatumomab Sensitive: C3 – Early Trials ponatinib + blinatumomab Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials ponatinib + blinatumomab Sensitive : C3	ponatinib + blinatumomab Sensitive: C3 – Early Trials ponatinib + blinatumomab Sensitive : C3
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3

Iclusig (ponatinib)

Associations
(98)

Associations
(98)

Iclusig (ponatinib)

Associations(98)

Associations(98)

Associations
(98)

Associations
(98)